Oruka Therapeutics, Inc. (ORKA) Tuesday announced positive interim data from its Phase 1 study evaluating the safety and pharmacokinetics of ORKA-001 in healthy volunteers.
ORKA-001, a long-acting monoclonal antibody targeting IL-23p19, is being investigated for the treatment of patients with Psoriasis.
In the Phase 1 study, ORKA-001 demonstrated an estimated half-life of about 100 days, suggesting the potential for once-yearly dosing, and was well tolerated with a favorable safety profile.
Initial data from the ongoing EVERLAST-A Phase 2a study are expected in the second half of 2026. Oruka also expects to initiate a Phase 2b study of ORKA-001 in patients with plaque psoriasis, dubbed EVERLAST-B, in the first half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.